92
Views
15
CrossRef citations to date
0
Altmetric
Original Research

Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza elicit protective virus neutralizing titers and cell-mediated immunity

, , , , , , , , , , , , & show all
Pages 229-243 | Published online: 30 Dec 2014

References

  • SubbaraoKKlimovAKatzJCharacterization of an avian influenza A (H5N1) virus isolated from a child with fatal respiratory illnessScience199827953493933969430591
  • NicholKLTreanorJJVaccines for seasonal and pandemic influenzaJ Infect Dis2006194Suppl 2S111S11817163383
  • PalesePShawMLOrthomyxoviridae: the viruses and their replicationKnipeDMHowleyPMFields VirologyPhiladelphia, PALippincott-Raven Publishers200716471689
  • OsterhausAFouchierRRimmelzwaanGTowards universal influenza vaccines?Philos Trans R Soc Lond B Biol Sci201136615792766277321893539
  • CoxMMPatriarcaPATreanorJFluBlok, a recombinant hemagglutinin influenza vaccineInfluenza Other Respir Viruses20082621121919453397
  • WeiCJXuLKongWPComparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virusJ Virol200882136200620818417563
  • CornelissenLAde VriesRPde Boer-LuijtzeEARigterARottierPJde HaanCAA single immunization with soluble recombinant trimeric hemagglutinin protects chickens against highly pathogenic avian influenza virus H5N1PLoS One201055e1064520498717
  • WeldonWCWangBZMartinMPKoutsonanosDGSkountzouICompansRWEnhanced immunogenicity of stabilized trimeric soluble influenza hemagglutininPLoS One201059pii:e12466
  • LoeffenWLde VriesRPStockhofeNVaccination with a soluble recombinant hemagglutinin trimer protects pigs against a challenge with pandemic (H1N1) 2009 influenza virusVaccine20112981545155021219983
  • de VriesRPSmitCHde BruinEGlycan-dependent immunogenicity of recombinant soluble trimeric hemagglutininJ Virol20128621117351174422915811
  • WangCCChenJRTsengYCGlycans on influenza hemagglutinin affect receptor binding and immune responseProc Natl Acad Sci U S A200910643181371814219822741
  • PrabakaranMMadhanSPrabhuNQiangJKwangJGastrointestinal delivery of baculovirus displaying influenza virus hemagglutinin protects mice against heterologous H5N1 infectionJ Virol20108473201320920071572
  • UleryBDKumarDRamer-TaitAEMetzgerDWWannemuehlerMJNarasimhanBDesign of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseasesPLoS One201163e1764221408610
  • KipperMJShenEDetermanASNarasimhanBDesign of an injectable system based on bioerodible polyanhydride microspheres for sustained drug deliveryBiomaterials200223224405441212219831
  • HuntimerLWilson WelderJHRossKSingle immunization with a suboptimal antigen dose encapsulated into polyanhydride microparticles promotes high titer and avid antibody responsesJ Biomed Mater Res B Appl Biomater20131011919823143744
  • KipperMJWilsonJHWannemuehlerMJNarasimhanBSingle dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanismJ Biomed Mater Res A200676479881016345084
  • HuntimerLMRossKADarlingRJPolyanhydride nanovaccine platform enhances antigen-specific cytotoxic T cell responsesTechnology201422171175
  • WoodlandDLHoganRJZhongWCellular immunity and memory to respiratory virus infectionsImmunol Res2001241536711485209
  • ThomasPGKeatingRHulse-PostDJDohertyPCCell-mediated protection in influenza infectionEmerg Infect Dis2006121485416494717
  • RossKALoydHWuWStructural and antigenic stability of H5N1 hemagglutinin trimer upon release from polyanhydride nanoparticlesJ Biomed Mater Res A2014102114161416824443139
  • BuehlerJLagerKVincentAMillerCThackerEJankeBIssues encountered in development of enzyme-linked immunosorbent assay for use in detecting influenza A virus subtype H5N1 exposure in swineJ Vet Diagn Invest201426227728124464555
  • WangWXieHYeZVassellRWeissCDCharacterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization asssaysJ Virol Methods2010165230531020153374
  • OlsenJCGene transfer vectors derived from equine infectious anemia virusGene Ther1998511148114879930301
  • TallmadgeRLBrindlyMASalmansJMealeyRHMauryWCarpenterSDevelopment and characterization of an equine infectious anemia virus Env-pseudotyped reporter virusClin Vaccine Immunol200815713814017978010
  • ConixAPoly[1,3-bis(p-carboxyphenoxy)-propane anhydride]Macromol Synth196629598
  • TorresMPVogelBMNarasimhanBMallapragadaSKSynthesis and characterization of novel polyanhydrides with tailored erosion mechanismsJ Biomed Mater Res A200676110211016138330
  • DetermanASGrahamJRPfeifferKANarasimhanBThe role of microsphere fabrication methods on the stability and release kinetics of ovalbumin encapsulated in polyanhydride microspheresJ Microencapsul200623883284317390625
  • Chavez-SantoscoyAVHuntimerLMRamer-TaitAEWannemuehlerMNarasimhanBHarvesting murine alveolar macrophages and evaluating cellular activation induced by polyanhydride nanoparticlesJ Vis Exp201264e388322710245
  • AlsharifiMFuruyaYBowdenTRIntranasal flu vaccine protective against seasonal and H5N1 avian influenza infectionsPLoS One200944e533619401775
  • UleryBDPetersenLKPhanseYRational design of pathogen-mimicking amphiphilic materials as nanoadjuvantsSci Rep2011119822355713
  • JolliffeeITPrincipal Component AnalysisSecaucus, NJSpringer2002
  • KoreniusTLaurikkalaJJuholaMOn principal component analysis, cosine, and Euclidean measures in information retrievalInf Sci20071772248934905
  • BroderickSRAouragHRajanKData mining of Ti–Al semi-empirical parameters for developing reduced order modelsPhysica B20114061120552060
  • McDonaldRSSambolARHeimbuchBKBrownTLHinrichsSHWanderJDProportional mouse model for aerosol infection by influenzaJ Appl Micro20121134767778
  • Centers for Disease Control and Prevention (CDC) [webpage on the Internet]Vaccine effectiveness-how well does the flu vaccine work? Available from: http://www.cdc.gov/flu/about/qa/vaccineeffect.htmAccessed June 12, 2014
  • US Food and Drug AdministrationH5N1 influenza virus vaccine, manufactured by Sanofi Pasteur, Inc. questions and answers Available from http://www.fda.gov/BiologicsBloodVaccines/Vaccines/QuestionsaboutVaccines/ucm080753.htmAccessed May 14, 2014
  • McElhaneyJEInfluenza vaccine responses in older adultsAgeing Res Rev201110337938821055484
  • HaynesLSwainSLWhy aging T cells fail: Implications for vaccinationImmunity200624666366616782020
  • SheridanPAPaichHAHandyJObesity is associated with impaired immune response to influenza vaccination in humansInt J Obes (Lond)20123681072107722024641
  • McKinstryKKStruttTMSwainSLHallmarks of CD4 T cell immunity against influenzaJ Intern Med2011269550751821362069
  • IchinoheTKawaguchiATamuraSIntranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challengeMicrobes Infect20079111333134017890128
  • PetersenLKPhaseYRamer-TaitAEWannemuehlerMJNarasimhanBAmphiphilic polyanhydride nanoparticles stabilize Bacillus anthracis protective antigenMol Pharm20129487488222380593